Syntara’s Amsulostat to Enter Phase 1/2 Pancreatic Cancer Trial with MRFF Funding
Syntara Limited (ASX: SNT) announced that the Garvan Institute of Medical Research has secured an AU$3 million grant from the Australian Government’s Medical Research Future Fund (MRFF) to fund two multicentre studies in advanced pancreatic cancer. One of these studies will evaluate Syntara’s investigational anti-fibrotic LOX inhibitor, amsulostat (SNT-5505), in combination with standard-of-care chemotherapy. Syntara will provide drug supply and clinical expertise, without any cash funding requirements.
This collaboration builds upon Garvan’s preclinical research, published in Nature Cancer, showing that targeting tumour fibrosis can improve chemotherapy effectiveness by enhancing drug penetration and reducing cancer cell metastasis. Recruitment for the study is scheduled to start in mid-2026 at major cancer centres across New South Wales. The studies will also incorporate precision medicine strategies to identify biomarkers and patient subgroups most likely to benefit, with broader implications for other solid cancers characterized by fibrous barriers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Syntara’s Amsulostat to Enter Phase 1/2 Pancreatic Cancer Trial with MRFF Funding
Syntara Limited (ASX: SNT) announced that the Garvan Institute of Medical Research has secured an AU$3 million grant from the Australian Government’s Medical Research Future Fund (MRFF) to fund two multicentre studies in advanced pancreatic cancer. One of these studies will evaluate Syntara’s investigational anti-fibrotic LOX inhibitor, amsulostat (SNT-5505), in combination with standard-of-care chemotherapy. Syntara will provide drug supply and clinical expertise, without any cash funding requirements.
This collaboration builds upon Garvan’s preclinical research, published in Nature Cancer, showing that targeting tumour fibrosis can improve chemotherapy effectiveness by enhancing drug penetration and reducing cancer cell metastasis. Recruitment for the study is scheduled to start in mid-2026 at major cancer centres across New South Wales. The studies will also incorporate precision medicine strategies to identify biomarkers and patient subgroups most likely to benefit, with broader implications for other solid cancers characterized by fibrous barriers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au